Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
1123 results:
1. [Genetic drivers for inflammatory protein markers in colorectal cancer: a Mendelian randomization approach to clinical prognosis study].
Li H; Li G; Zhang X; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Jul; 44(7):1361-1369. PubMed ID: 39051082
[TBL] [Abstract] [Full Text] [Related]
2. Cross-cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER.
Koga K; Tasaka Y; Nawa H
Biol Pharm Bull; 2024; 47(7):1296-1300. PubMed ID: 39010215
[TBL] [Abstract] [Full Text] [Related]
3. Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis.
Yu H; Liu Q; Wu K; Tang S
Clin Exp Med; 2024 Jul; 24(1):143. PubMed ID: 38960935
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of Tumor Non-specific and pd-l1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging.
Zhang L; Zhao L; Lin X; Zhao S; Pan W; Wang D; Sun Z; Li J; Liang Z; Zhang R; Jiang H
Mol Imaging; 2024; 23():15353508241261473. PubMed ID: 38952401
[TBL] [Abstract] [Full Text] [Related]
5. Expression of pd-l1 Is Increased by Methionine Restriction Using Recombinant Methioninase in Human colorectal cancer Cells.
Mizuta K; Kang BM; Han Q; Kubota Y; Morinaga S; Sato M; Bouvet M; Tome Y; Nishida K; Hoffman RM
Cancer Genomics Proteomics; 2024; 21(4):395-398. PubMed ID: 38944421
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic and therapeutic insights into colorectal carcinoma through immunogenic cell death gene profiling.
Yu J; Gong Y; Xu Z; Chen L; Li S; Cui Y
PeerJ; 2024; 12():e17629. PubMed ID: 38938617
[TBL] [Abstract] [Full Text] [Related]
7. Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-pd-l1 therapy.
Yang Z; Chu B; Tu Y; Li L; Chen D; Huang S; Huang W; Fan W; Li Q; Zhang C; Yuan Z; Huang J; Leung EL; Jiang Y
Pharmacol Res; 2024 Aug; 206():107271. PubMed ID: 38906202
[TBL] [Abstract] [Full Text] [Related]
8. Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors.
Berland L; Gabr Z; Chang M; Ilié M; Hofman V; Rignol G; Ghiringhelli F; Mograbi B; Rashidian M; Hofman P
Front Immunol; 2024; 15():1384121. PubMed ID: 38903504
[TBL] [Abstract] [Full Text] [Related]
9. Rapamycin circumvents anti PD-1 therapy resistance in colorectal cancer by reducing pd-l1 expression and optimizing the tumor microenvironment.
Jia M; Yuan Z; Yu H; Feng S; Tan X; Long Z; Duan Y; Zhu W; Yan P
Biomed Pharmacother; 2024 Jul; 176():116883. PubMed ID: 38876047
[TBL] [Abstract] [Full Text] [Related]
10. Tumor-infiltrating lymphocytes, pd-l1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from immunotherapy.
Giatromanolaki A; Kavazis C; Gkegka AG; Kouroupi M; Tsaroucha A; Pitiakoudis M; Koukourakis MI
Immunobiology; 2023 Nov; 228(6):152756. PubMed ID: 38860277
[TBL] [Abstract] [Full Text] [Related]
11. The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.
Yang L; Cui X; Wu F; Chi Z; Xiao L; Wang X; Liang Z; Li X; Yu Q; Lin X; Gao C
Front Immunol; 2024; 15():1392499. PubMed ID: 38846948
[TBL] [Abstract] [Full Text] [Related]
12. PPARα phosphorylation regulates colorectal tumor immune escape.
Gou Q; Tian X; Dong C; Yan B; Chen M; Shi J; Yang L; Hou Y
J Biol Chem; 2024 Jul; 300(7):107447. PubMed ID: 38844134
[TBL] [Abstract] [Full Text] [Related]
13. Dysfunctional circadian clock accelerates cancer metastasis by intestinal microbiota triggering accumulation of myeloid-derived suppressor cells.
Liu JL; Xu X; Rixiati Y; Wang CY; Ni HL; Chen WS; Gong HM; Zhang ZL; Li S; Shen T; Li JM
Cell Metab; 2024 Jun; 36(6):1320-1334.e9. PubMed ID: 38838643
[TBL] [Abstract] [Full Text] [Related]
14. Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
Nie H; Yu Y; Wang F; Huang X; Wang H; Wang J; Tao M; Ning Y; Zhou J; Zhao Q; Xu F; Fang J
Cancer Immunol Immunother; 2024 Jun; 73(8):156. PubMed ID: 38834869
[TBL] [Abstract] [Full Text] [Related]
15. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
Tsukada Y; Bando H; Inamori K; Wakabayashi M; Togashi Y; Koyama S; Kotani D; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Sato A; Nishikawa H; Ito M; Yoshino T
Br J Cancer; 2024 Jul; 131(2):283-289. PubMed ID: 38834744
[TBL] [Abstract] [Full Text] [Related]
16. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade.
Zhao L; Pang Y; Zhou Y; Chen J; Fu H; Guo W; Xu W; Xue X; Su G; Sun L; Wu H; Zhang J; Wang Z; Lin Q; Chen X; Chen H
Signal Transduct Target Ther; 2024 Jun; 9(1):142. PubMed ID: 38825657
[TBL] [Abstract] [Full Text] [Related]
17. Blue light irradiation inhibits the M2 polarization of the cancer-associated macrophages in colon cancer.
Yoshimoto T; Nishi M; Okikawa S; Yoshikawa K; Tokunaga T; Nakao T; Takasu C; Kashihara H; Wada Y; Noma T; Shimada M
BMC Cancer; 2024 May; 24(1):664. PubMed ID: 38822331
[TBL] [Abstract] [Full Text] [Related]
18. Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan.
Takahashi R; Osumi H; Wakatsuki T; Yamamoto N; Taguchi S; Nakayama I; Ooki A; Ogura M; Takahari D; Chin K; Yamaguchi K; Shinozaki E
Int J Clin Oncol; 2024 Aug; 29(8):1161-1172. PubMed ID: 38819609
[TBL] [Abstract] [Full Text] [Related]
19. PD-1/pd-l1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
[TBL] [Abstract] [Full Text] [Related]
20. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade.
Fortin BM; Pfeiffer SM; Insua-Rodríguez J; Alshetaiwi H; Moshensky A; Song WA; Mahieu AL; Chun SK; Lewis AN; Hsu A; Adam I; Eng OS; Pannunzio NR; Seldin MM; Marazzi I; Marangoni F; Lawson DA; Kessenbrock K; Masri S
Nat Immunol; 2024 Jul; 25(7):1257-1269. PubMed ID: 38806707
[TBL] [Abstract] [Full Text] [Related]
[Next]
